These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 17614238)

  • 1. Economic benefit of chemical dependency treatment to employers.
    Jordan N; Grissom G; Alonzo G; Dietzen L; Sangsland S
    J Subst Abuse Treat; 2008 Apr; 34(3):311-9. PubMed ID: 17614238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling the impact of enhanced depression treatment on workplace functioning and costs: a cost-benefit approach.
    Lo Sasso AT; Rost K; Beck A
    Med Care; 2006 Apr; 44(4):352-8. PubMed ID: 16565636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using the interaction of mental health symptoms and treatment status to estimate lost employee productivity.
    Hilton MF; Scuffham PA; Vecchio N; Whiteford HA
    Aust N Z J Psychiatry; 2010 Feb; 44(2):151-61. PubMed ID: 20113304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and benefit-cost of peer-based workplace substance abuse prevention coupled with random testing.
    Miller TR; Zaloshnja E; Spicer RS
    Accid Anal Prev; 2007 May; 39(3):565-73. PubMed ID: 17125723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Workplace smoking related absenteeism and productivity costs in Taiwan.
    Tsai SP; Wen CP; Hu SC; Cheng TY; Huang SJ
    Tob Control; 2005 Jun; 14 Suppl 1(Suppl 1):i33-7. PubMed ID: 15923446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The economics of mental health in the workplace: what do we know and where do we go?
    McDaid D
    Epidemiol Psichiatr Soc; 2007; 16(4):294-8. PubMed ID: 18333424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of a mixed-gender aftercare program for substance abuse: decomposing measured and unmeasured gender differences.
    Yeom HS; Shepard DS
    J Ment Health Policy Econ; 2007 Dec; 10(4):207-19. PubMed ID: 18166831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective.
    Lamb CE; Ratner PH; Johnson CE; Ambegaonkar AJ; Joshi AV; Day D; Sampson N; Eng B
    Curr Med Res Opin; 2006 Jun; 22(6):1203-10. PubMed ID: 16846553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substance abuse and the uninsured worker in the United States.
    Galvin DM; Miller TR; Spicer RS; Waehrer GM
    J Public Health Policy; 2007; 28(1):102-17. PubMed ID: 17363941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
    Weaver MR; Conover CJ; Proescholdbell RJ; Arno PS; Ang A; Uldall KK; Ettner SL
    J Ment Health Policy Econ; 2009 Mar; 12(1):33-46. PubMed ID: 19346565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The productivity assessment tool: computer-based cost benefit analysis model for the economic assessment of occupational health and safety interventions in the workplace.
    Oxenburgh M; Marlow P
    J Safety Res; 2005; 36(3):209-14. PubMed ID: 16038939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of a workplace intervention for sick-listed employees with distress.
    van Oostrom SH; Heymans MW; de Vet HC; van Tulder MW; van Mechelen W; Anema JR
    Occup Environ Med; 2010 Sep; 67(9):603-10. PubMed ID: 20798027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Employer costs of alcohol-involved injuries.
    Zaloshnja E; Miller TR; Hendrie D; Galvin D
    Am J Ind Med; 2007 Feb; 50(2):136-42. PubMed ID: 17187380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Workplace accommodations: evidence based outcomes.
    Schartz HA; Hendricks DJ; Blanck P
    Work; 2006; 27(4):345-54. PubMed ID: 17148871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Net-cost model for workplace interventions.
    Lahiri S; Gold J; Levenstein C
    J Safety Res; 2005; 36(3):241-55. PubMed ID: 16038937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administrative issues related to addiction in the workplace.
    Roberts S; Fallon LF
    Occup Med; 2001; 16(3):509-15, v. PubMed ID: 11401795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Assessment of cost-benefit analysis in integration projects on drug addiction].
    Ates T; Langer B; Erbas B; Tretter F; Wehner B
    Gesundheitswesen; 2005 Feb; 67(2):159-62. PubMed ID: 15747208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost-benefit analysis of primary prevention programs for mental health at the workplace in Japan].
    Yoshimura K; Kawakami N; Tsusumi A; Inoue A; Kobayashi Y; Takeuchi A; Fukuda T
    Sangyo Eiseigaku Zasshi; 2013; 55(1):11-24. PubMed ID: 23257469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prevention of overweight and obesity in the workplace. BASF-health promotion campaign "trim down the pounds--losing weight without losing your mind"].
    Oberlinner C; Lang S; Germann C; Trauth B; Eberle F; Pluto R; Neumann S; Zober A
    Gesundheitswesen; 2007 Jul; 69(7):385-92. PubMed ID: 17701837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.